Zacks Small Cap Issues Negative Outlook for MIRA Earnings

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) – Research analysts at Zacks Small Cap decreased their Q4 2024 EPS estimates for shares of MIRA Pharmaceuticals in a research note issued on Thursday, December 19th. Zacks Small Cap analyst B. Sorensen now expects that the company will post earnings of ($0.29) per share for the quarter, down from their prior estimate of ($0.19). The consensus estimate for MIRA Pharmaceuticals’ current full-year earnings is ($0.60) per share. Zacks Small Cap also issued estimates for MIRA Pharmaceuticals’ FY2026 earnings at ($0.54) EPS.

MIRA Pharmaceuticals (NASDAQ:MIRA) last released its earnings results on Tuesday, November 12th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04.

Several other equities analysts also recently weighed in on the company. RODMAN&RENSHAW raised MIRA Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. Rodman & Renshaw started coverage on MIRA Pharmaceuticals in a report on Monday, September 30th. They issued a “buy” rating and a $17.00 price objective for the company.

MIRA Pharmaceuticals Price Performance

NASDAQ MIRA opened at $1.10 on Monday. The business has a 50 day simple moving average of $1.36 and a two-hundred day simple moving average of $1.37. MIRA Pharmaceuticals has a 1-year low of $0.51 and a 1-year high of $5.01. The stock has a market capitalization of $18.22 million, a PE ratio of -1.96 and a beta of 1.98.

Hedge Funds Weigh In On MIRA Pharmaceuticals

An institutional investor recently raised its position in MIRA Pharmaceuticals stock. Suncoast Equity Management grew its stake in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) by 125.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 90,000 shares of the company’s stock after buying an additional 50,000 shares during the period. Suncoast Equity Management owned 0.61% of MIRA Pharmaceuticals worth $117,000 at the end of the most recent quarter. 35.16% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at MIRA Pharmaceuticals

In other news, CEO Erez Aminov sold 55,410 shares of MIRA Pharmaceuticals stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $1.39, for a total value of $77,019.90. Following the transaction, the chief executive officer now owns 1,105,790 shares of the company’s stock, valued at $1,537,048.10. The trade was a 4.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.65% of the company’s stock.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.